Covariance adjustment of survival curves based on Cox's proportional hazards regression model
Department of Community, Occupational and Family Medicine, National University of Singapore Lower Kent Ridge Road, Singapore 0511
1Berlex Laboratories Inc, Alameda, CA
2Cancer Research Center of Hawaii Honolulu, HI, USA
Cox's proportional hazards regression model is a useful statistical tool for the analysis of survival data from longitudinal studies. This multivariate method compares the survival experience between two or more exposure groups while allowing for simultaneous adjustment of confounding due to one or more covariates. In addition to the summary regression statistics, further insight on the exposureresponse relationship can be gained by visually examining the covariatesadjusted survival curves in the respective comparison groups. Covariatesadjusted survival curves are usually computed by the average covariate method. This method is, however, subject to potential drawbacks. A method that avoids these drawbacks is to estimate adjusted survival curves by the corrected group prognostic curves approach. We have written a computer program to construct survival curves by the latter method. The program is coded in the Interactive Matrix Language of SAS.
Received on March 5, 1991; accepted on August 16, 1991
This article has been cited by other articles:
![]() |
D. T. Mangano, Y. Miao, A. Vuylsteke, I. C. Tudor, R. Juneja, D. Filipescu, A. Hoeft, M. L. Fontes, Z. Hillel, E. Ott, et al. Mortality Associated With Aprotinin During 5 Years Following Coronary Artery Bypass Graft Surgery JAMA, February 7, 2007; 297(5): 471 - 479. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Beinart, P. Kolm, E. Veledar, Z. Zhang, E. M. Mahoney, O. Bouin, S. Gabriel, J. Jackson, R. Chen, J. Caro, et al. Long-Term Cost Effectiveness of Early and Sustained Dual Oral Antiplatelet Therapy With Clopidogrel Given for Up to One Year After Percutaneous Coronary Intervention: Results From the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial J. Am. Coll. Cardiol., September 6, 2005; 46(5): 761 - 769. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. S. Weintraub, E. M. Mahoney, A. Lamy, S. Culler, Y. Yuan, J. Caro, S. Gabriel, S. Yusuf, and CURE Study Investigators Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation J. Am. Coll. Cardiol., March 15, 2005; 45(6): 838 - 845. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. P. Vivekananthan, E. H. Blackstone, C. E. Pothier, and M. S. Lauer Heart rate recovery after exercise is apredictor of mortality, independent of the angiographic severity of coronary disease J. Am. Coll. Cardiol., September 3, 2003; 42(5): 831 - 838. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. A. Ghali, H. Quan, R. Brant, G. van Melle, C. M. Norris, P. D. Faris, P. D. Galbraith, M. L. Knudtson, and for the APPROACH Investigators Comparison of 2 Methods for Calculating Adjusted Survival Curves From Proportional Hazards Models JAMA, September 26, 2001; 286(12): 1494 - 1497. [Abstract] [Full Text] [PDF] |
||||

